151. Risk of Reflux-Related Symptoms and Reflux Esophagitis after Helicobacter pylori Eradication Treatment in the Japanese Population
- Author
-
Takao Itoi, Eri Iwata, Masaki Murata, Takashi Kawai, Naoyoshi Nagata, and Mitsushige Sugimoto
- Subjects
medicine.medical_specialty ,Prevalence ,lcsh:Medicine ,macromolecular substances ,Gastroenterology ,Article ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Reflux esophagitis ,Risk factor ,gastric acid ,biology ,Helicobacter pylori ,business.industry ,lcsh:R ,Reflux ,General Medicine ,Odds ratio ,GERD ,questionnaires ,medicine.disease ,biology.organism_classification ,Confidence interval ,030220 oncology & carcinogenesis ,030211 gastroenterology & hepatology ,eradication therapy ,business - Abstract
Backgrounds: A meta-analysis of reports primarily from Western countries showed no association between Helicobacter pylori eradication and reflux esophagitis development. The risk of reflux esophagitis may differ among different populations based on H. pylori virulence factors and acid secretion ability. We evaluated the prevalence rates of reflux esophagitis in H.-pylori-positive Japanese subjects and assessed risk factors for reflux esophagitis after eradication. Methods: Among 148 H.-pylori-positive subjects who underwent H. pylori eradication from August 2015 to December 2019, we evaluated the prevalence of reflux esophagitis on endoscopy at 12 months after eradication success and the severity of reflux-related symptoms by the F-scale questionnaire at 2 months after treatment and 12 months after eradication success. Results: The prevalence of reflux esophagitis in H.-pylori-positive patients at entry was 2.0% (3/148). At 12 months after eradication success, the prevalence was 10.8% (16/148) (p <, 0.01). In the F scale, the median total score before treatment was 4 (range: 0–49), which significantly decreased to 2 (range: 0–22) (p <, 0.01) at 2 months after treatment and 3 (range: 0–23) (p <, 0.01) at 12 months after eradication success. Following multivariate analysis, the pretreatment total F-scale score was a risk factor for the development of reflux esophagitis (odds ratio: 1.069, 95% confidence interval: 1.003–1.139, p <, 0.01). Conclusions: In this H.-pylori-positive Japanese population, eradication therapy was associated with reflux esophagitis in around 10% of patients, particularly in those with severe reflux-related symptoms at baseline. Reflux-related symptoms may improve throughout the 12 months after successful eradication therapy, irrespective of the development of reflux esophagitis.
- Published
- 2021
- Full Text
- View/download PDF